CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
Authors
P. Agudo
M. Areses Manrique
+23 more
F. Arnalich Fernández
A. Artero
A.D. Bendala Estrada
M. Bustamante
J. Calderón Parra
H.F.J. Carrasco-Sánchez
J.-M. Casas-Rojo
A. Crestelo Vieitez
P. Cubero-Morais
V. Estrada Perez
E. Fernández Carracedo
S.J. Freire
G.M. García García
A. Muiño Míguez
E. Muñez Rubio
J.M. Núñez-Cortés
J. Olalla Sierra
I. Oriol-Bermúdez
P.M. Pesqueira Fontan
A. Ramos Martínez
M. Rubio-Rivas
M.L. Taboada Martínez
V.C. Vento
Publication date
1 January 2021
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Background: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality. Results: Of 13, 932 patients, antibiotics were used in 12, 238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62; p <.001) except macrolides, which had a higher survival rate (OR 0.70, 95% CI 0.64–0.76; p <.001). The decision to start antibiotics was influenced by presence of increased inflammatory markers and any kind of infiltrate on an x-ray. Patients receiving antibiotics required respiratory support and were transferred to intensive care units more often. Conclusions: Bacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment. © 2021, The Author(s)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Repositorio Universidad de Zaragoza
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:zaguan.unizar.es:112525
Last time updated on 02/07/2022